Premium
The therapeutic effect of B‐type natriuretic peptides in acute decompensated heart failure
Author(s) -
Caprnda Martin,
Zulli Anthony,
Shiwani Haaris A.,
Kubatka Peter,
Filipova Slavomira,
Valentova Vanda,
Gazdikova Katarina,
Mozos Ioana,
Berukstis Andrius,
Laucevicius Aleksandras,
Rihacek Ivan,
Dragasek Jozef,
Prosecky Robert,
Egom Emmanuel E.,
Staffa Robert,
Kruzliak Peter,
Krasnik Vladimir
Publication year - 2020
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13290
Subject(s) - natriuresis , medicine , diuresis , natriuretic peptide , heart failure , acute decompensated heart failure , intensive care medicine , clinical trial , cardiorenal syndrome , cardiology , renal function
B‐type natriuretic peptide (BNP) exhibits roles in natriuresis and diuresis, making it an ideal drug that may aid in diuresing a fluid‐overloaded patient with poor or worsening renal function. Several randomized clinical trials have tested the hypothesis that infusions of pharmacological doses of BNP to acute heart failure (HF) patients may enhance decongestion and preserve renal function in this clinical setting. Unfortunately, none of these have demonstrated beneficial outcomes. The current challenge for BNP research in acute HF lies in addressing a failure of concept and a reluctance to abandon an ineffective research model. Future success will necessitate a detailed understanding of the mechanism of action of BNP, as well as better integration of basic and clinical science.